Innate Pharma (IPHA) Cash from Investing Activities (2019 - 2023)

Innate Pharma (IPHA) has 5 years of Cash from Investing Activities data on file, last reported at -$267875.4 in Q2 2023.

• Quarterly Cash from Investing Activities rose 36.45% year-over-year to -$267875.4 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$2.0 million (up 88.5% YoY) and the FY2025 annual result came in at $8.5 million, down 13.69% from the prior year.
• Cash from Investing Activities advanced to -$267875.4 in Q2 2023, from -$421487.4 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$267875.4 in Q2 2023 to a low of -$69.4 million in Q2 2019.
• A 5-year average of -$21.2 million and a median of -$7.2 million in 2020 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2021 — Cash from Investing Activities surged 97.77% — and 2022, when it sank 41.7%.
• Tracing IPHA's Cash from Investing Activities over 5 years: stood at -$68.8 million in 2019, then jumped by 76.82% to -$15.9 million in 2020, then jumped by 93.42% to -$1.0 million in 2021, then surged by 59.82% to -$421487.4 in 2022, then soared by 36.45% to -$267875.4 in 2023.
• The last three Cash from Investing Activities figures came in at -$267875.4 (Q2 2023), -$421487.4 (Q2 2022), and -$1.0 million (Q4 2021), per Business Quant data.